Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

LOS ANGELES--(BUSINESS WIRE)--Vance Street Capital LLC (“Vance Street”) is pleased to announce it has completed the sale of A&E Medical Corporation (“A&E Medical”) to Zimmer Biomet (NYSE: ZBH) (“Zimmer”), a global leader in musculoskeletal healthcare, for $250 million. The transaction marks the second exit out of Vance Street's Sophomore Fund. Founded in 1968 and headquartered in Farmingdale, New Jersey, A&E Medical is a leading designer and manufacturer of a comprehensive portfolio

Vance Street Capital Recognizes Successful Exit of A&E Medical Corporation to Zimmer Biomet

WARSAW, Ind., Dec. 1, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today officially launched the Zimmer Biomet Foundation. The Foundation is a philanthropic 501(c)(3) organization that further strengthens the...

Zimmer Biomet Foundation Launches, Supporting Diverse and Underserved Communities, STEM Education, Community Health and Disaster Relief

Zimmer Biomet has exited the 3rd quarter better than expected, with tailwinds in hips and knees globally to drive top-line growth in years to come. The ROSA and Persona Revision segments have performed well YTD, alongside ~10% growth in US hips, which shows the orthopaedics market has made a recovery.

Zimmer Biomet: Secure Play For Orthopaedics Exposure, +20% Upside

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q3 2020 Results - Earnings Call Transcript

The company's recovery from the coronavirus pandemic was better than expected.

How Zimmer Biomet Zoomed Past Wall Street's Third-Quarter Estimates

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

Zimmer (ZBH) delivered earnings and revenue surprises of 72.38% and 12.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Beats Q3 Earnings and Revenue Estimates

  Shares of Zimmer Biomet Holdings (NYSE:ZBH) were unchanged after the company reported Q3 results.

Zimmer Biomet: Q3 Earnings Insights

WARSAW, Ind., Nov. 6, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2020. The Company reported third quarter net sales of $1.929 billion, an increase of 2.0% over the prior year period, and an...

Zimmer Biomet Announces Third Quarter 2020 Financial Results

WARSAW, Ind., Nov. 5, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced preliminary results from a prospective, randomized controlled clinical trial to evaluate the impact of mymobility® with Apple...

Zimmer Biomet Announces Preliminary Results from mymobility® Clinical Study at 2020 AAHKS Annual Meeting

HMS Hlds

Hill-Rom Hlds

Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how ZBH, HRC and HMS are poised ahead of their announcements.

Medical Products Stock Earnings on Nov 6: ZBH, HRC and HMSY

WARSAW, Ind., Nov. 2, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal care, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the Stifel Virtual Healthcare...

Zimmer Biomet to Present at Stifel Virtual Healthcare Conference

WARSAW, Ind., Oct. 6, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Friday, November 6, 2020, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that...

Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2020 Financial Results

AbbVie

Boston Scientific

Medtronic

Stryker

While technology has been the engine that has driven stock market performance for some time now, increasingly we are seeing a seismic shift to health care among many portfolio managers, and with good reason.

Top Analyst Very Positive on Leading Medical Technology Health Care Stocks for 2021

WARSAW, Ind., Sept. 10, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2020

WARSAW, Ind., Sept. 8, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.

Zimmer Biomet to Present at Morgan Stanley Virtual Global Healthcare Conference

Abbott Labs

General Electric

Myriad Genetics

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

3 Coronavirus-Led Threats to MedTech That May Linger

Zimmer Biomet Holdings, Inc. (ZBH) CEO Bryan Hanson on Q2 2020 Results - Earnings Call Transcript

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

Zimmer (ZBH) delivered earnings and revenue surprises of 106.94% and 31.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates

WARSAW, Ind., Aug. 4, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.

Zimmer Biomet Announces Second Quarter 2020 Financial Results

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zimmer Biomet Holdings Inc (NASDAQ: ZBH) shares are trading higher on Wednesday after SVB Leerink maintained a Buy rating on the stock and raised its price target from $136 to $146.

Why Zimmer Biomet's Stock Is Trading Higher Today

Smith & Nephew

The pandemic hit Zimmer, Smith+Nephew, and Stryker hard -- but they'll soon rise again.

News for Zimmer Biomet Hlds Stock (ZBH)